TANDEM DIABETES CARE INC TNDM

Rank #2187 · Nasdaq · $1.3B market cap

Audited by Ernst & Young LLP, no going-concern flag in the latest filing.

Score

30.0

P/E

-5.9

P/B

2.98

ROE

-50.6%

Op. Margin

-31.2%

Debt Ratio

160%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆

Weak

P/E -5.9x, P/B 2.98x. Ranks in the top 70% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -50.6%. Ranks in the top 86% of the universe.

Safety ★★☆☆☆

Average

Debt ratio 160%. Ranks in the top 55% of the universe.

Growth ★☆☆☆☆

Weak

Revenue decline of 6.7% year over year. Ranks in the top 79% of the universe.

Valuation is the relative strength · Profitability is the relative weakness (relative to this universe).

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2014	–	$-0.0B	$-0.0B	$-0.1B	–	-65
2015	–	$-0.0B	$-0.1B	$-0.1B	–	-49
2016	–	$-0.1B	$-0.1B	$0.1B	–	53
2017	–	$-0.1B	$-0.1B	$0.1B	–	217
2018	$0.1B	$-0.1B	$-0.1B	$0.1B	-92.6	196
2019	$0.1B	$-0.1B	$-0.1B	$-0.0B	-58.5	-1266
2020	$0.2B	$-0.0B	$-0.1B	$-0.0B	-24.3	-450
2021	$0.4B	$-0.0B	$-0.0B	$0.1B	-4.6	267
2022	$0.5B	$-0.0B	$-0.0B	$0.2B	-1.6	242
2023	$0.7B	$0.0B	$0.0B	$0.4B	3.2	167
2024	$0.8B	$-0.1B	$-0.1B	$0.4B	-11.6	148
2025	$0.7B	$-0.2B	$-0.2B	$0.4B	-31.2	160